Coherus Biosciences | CHRS - Trade Debtors


Coherus Biosciences reported $18.42M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
ALKERMES USD 456.48M 48.85M Jun/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amarin USD 126.83M 477K Dec/2025
Amgen USD 10.23B 1.09B Jun/2026
Baxter International USD 1.86B 158M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 23.48B 2.3B Jun/2026
Fujifilm JPY 887.02B 64.37B Mar/2026
Gilead Sciences USD 5.06B 314M Jun/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Merck USD 12.21B 435M Mar/2026
Myriad Genetics USD 115.3M 2.7M Dec/2025
Pacira USD 132.42M 6.78M Jun/2026
Perrigo USD 697.1M 84.3M Mar/2026
Pfizer USD 16.19B 19M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
Teva Pharmaceutical Industries USD 3.49B 100M Jun/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026
Xencor USD 42.23M 30.23M Jun/2026
Zoetis USD 1.57B 65M Jun/2026